Search This Blog

Tuesday, March 31, 2020

InflaRx doses first COVID-19 with IFX-1; shares up 24% after hours

InflaRx N.V. (NASDAQ:IFRX) announces that dosing is underway in a randomized clinical trial evaluating IFX-1 in patients with severe COVID-19-induced pneumonia.
It says IFX-1 is a monoclonal anti-human complement factor C5a antibody designed to induce an anti-inflammatory response by blocking the biological activity of C5a.
Shares up 24% after hours.
https://seekingalpha.com/news/3556994-inflarx-doses-first-covidminus-19-ifxminus-1-shares-up-24-after-hours

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.